All News
PMR & Popeye's Spinach (10.6.2023)
Dr. Jack Cush reviews the big PMR reports from this week along with other journal reports from RheumNow.com.
Read Article
Sustained Efficacy of Bimekizumab in Psoriatic Arthritis
BE OPTIMAL trial tested the benefits of a dual IL-17 A/F inhibitor, bimekizumab (BKZ), in patients with active psoriatic arthritis and showed superior efficacy over placebo, that was sustained beyond the primary endpoint, from week 16 to 52.
Read Article
SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica
NEJM reported today that polymyalgia rheumatica (PMR) patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).
Read Article
Predictive FDG-PET in Newly Diagnosed GCA
Annals of Internal Medicine reports that the use of 18F-fluorodeoxyglucose (FDG) PET imaging at the time of a giant cell arteritis (GCA) diagnosis may help estimate the risk for aortic aneurysm formation.
Read Article
Registration is now open! Early bird pricing is available until 11/30/23. See you there!
https://t.co/zEf9KTXYqX https://t.co/eQTQzgJpVF
Links:
Dr. John Cush RheumNow ( View Tweet)
The frequency of demyelinating Dz (DD) studied in 2260 #SpA pts, finging 18 DD events (IR 31 per 100K PYs) DD at 20 yrs was higher in axSpA than PsA (1.30 vs 0.13%, p= 0.01). DD risk w/ smoking (HR 2.9), axSpA (8.8) & IBD (5.7) -- NOT TNFi! https://t.co/IVoCxd6H0D https://t.co/FQtHuUWYUx
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Steroid Response for a #PMR Diagnosis
Featuring Dr. Jack Cush (Dallas, TX): Exquisite response to prednisone but other red flags!
https://t.co/DCtcZqG5NE https://t.co/Rs9rfds5w0
Dr. John Cush RheumNow ( View Tweet)
TNR: #PMR Diagnosis and Monitoring
Tuesday Night Rheumatology webinar on the diagnosis and monitoring of PMR.
Featuring Panelists, Drs. Claire Owen, Anisha Dua, Stephen Paget and moderated by Jack Cush.
https://t.co/7ewWLAUf4N
@anisha_dua @Rheummd @drceowen https://t.co/GCtYUHBPba
Dr. John Cush RheumNow ( View Tweet)
Multinational study of 47 studies of 11,085 #RA pts showed the prevalence of ANXIETY to range from 2.4% to 77%. Variance due to inconsistent, non-standardized self-report measures and clinical thresholds. Common; but how common? https://t.co/elcxjfSI7N https://t.co/iRNeQy4pEk
Dr. John Cush RheumNow ( View Tweet)
Network metanalysis review of 65 trials (n=5957) looked at Tx effect in Hand #OA. Whereas oral NSAIDs & glucocorticoids’ NMA were effective compared with placebo; intraarticular steroid & hyaluronate, and HCQ and topical NSAIDs were NOT. https://t.co/8CCkfWd80E https://t.co/jpqlq8Xwgp
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Difficult #PMR Considerations
Featuring Dr. Sarah Mackie (Leeds, UK) Difficulty weaning prednisone leads to consideration of other confounders and conditions QD Clinics are video vignettes with lessons from the clinic.
https://t.co/H6cZaMperr
@Sarah_L_Mackie https://t.co/WtCX6xfWe3
Dr. John Cush RheumNow ( View Tweet)
Gout Flare Prophylaxis - Colchicine or NSAIDs?
A new study suggests that colchicine, more so than non-steroidal anti-inflammatory drug (NSAID) prophylaxis, may increase the odds of adverse events, when initiating allopurinol for gout.
https://t.co/MfVvBy0DsD https://t.co/jP5oiAHaBa
Dr. John Cush RheumNow ( View Tweet)
Subclinical vasculitis in PMR
For a long time #PMR has been an underinvestigated disease. This is changing with new possibilities to make a more accurate diagnosis with imaging as well as new therapies for treatment resistant disease.
https://t.co/t0BRosgMWt https://t.co/bWZzRidqlm
Dr. John Cush RheumNow ( View Tweet)
Subclinical GCA prevalence in newly Dx #PMR ranges from 23 to 29%; best by Vessel imaging or temporal artery Bx. #PMR & GCA share common genetic/pathogenic inflammatory mechanisms & an IL-6 signature; BUT there are differences; further research needed! https://t.co/MhuIs068NG https://t.co/1BeeP3RY0H
Dr. John Cush RheumNow ( View Tweet)
GCA pts w/ prior #PMR Dx had 2 fold more Lg vessel dz & signif more vasculitic stenoses. Study of 311 GCA pts, 16% had prior PMR ~ 31 mos before. prior PMR had more LVV (51 vs 25%) & stenosis(18 vs 3%). Prior PMR incr LVV (OR 7.65) https://t.co/1kqtkPnPaz https://t.co/oVs084NfmV
Dr. John Cush RheumNow ( View Tweet)
JAKi Safety & Efficacy in bDMARD-IR Patients with RA: Results Through 5 Years
This poster shows 5-year outcomes from the SELECT-BEYOND study in bDMARD-IR patients with RA, including TNFi-IR subgroup outcomes. Sponsored by AbbVie US Medical Affairs https://t.co/BRsCMnOnFT . https://t.co/lxfPs12mHb
Dr. John Cush RheumNow ( View Tweet)
Best quote from last nights Tues Night Rheumatology on #PMR , comes from Dr. Stephen Paget (#HSS) who said, "steroids to a new PMR patient are like spinach to Popeye" https://t.co/r7L1cUTJeT
Dr. John Cush RheumNow ( View Tweet)
X-sectional case-cntrl study w/ UK Biobank looked @ comorbidity w #PMR (n=1036) & GCA (102) pts (98% W; age 63 yrs) - pts rated their health as poor. Comorbid Dx included-more hypothyroidism (OR 1.34), HRT use (1.26), HTN (1.21-1.86) & cataract (1.51-3.84) https://t.co/GxpzN5NWug https://t.co/8J0IRMLK5g
Dr. John Cush RheumNow ( View Tweet)
New download on #PMR available now!
https://t.co/C4fCUQ5j8e https://t.co/3Fm5xG8EM7
Dr. John Cush RheumNow ( View Tweet)
Steroid Tapering in #PMR: What's the Gold Standard?
Dr. Anisha Dua, Chicago, discusses the gold standard tapering of glucocorticoids in polymyalgia rheumatica.
https://t.co/WyojhJQkN2 https://t.co/NarFqwNxEj
Dr. John Cush RheumNow ( View Tweet)
